Formulary Watch |

Pfizer bucks the trend with as high as 98.5% price cuts.

Approval of Ubrelvy follows several new migraine drugs.

Diabetes and hypertension are among the primary diseases included.

The fish oil drug is approved to reduce cardiovascular risk. 

Alkermes omitted warnings about serious risks from taking the drug.

Stephen Hahn is confirmed by the U.S. Senate.

Hospitals sue over drug price disclosure rule.

This is the agency’s first generic approvals of Gilenya.

Approval made via international collaborative effort.

Federal subpoenas are latest in opioid actions.

FDA cites 15 companies making unsubstantiated health claims.

PBM mergers contribute to pricing problems, ACP says.

Trump claims lower drug prices, fights Pelosi bill.

FDA and Congress are putting forth new proposals to mitigate drug shortages, which continue to have a major impact on the US healthcare system.

Pharma maker develops biosimilars to Lucentis, Eyelea. 

Sandoz now has 2 biosimilars to the popular cancer drug.

Health groups had urged Trump to make a different choice.

PBM’s Medicare plan includes deep discounts

Researchers find lower lung function after inhaler change.

This is the eighth indication approved for Xarelto.

Here are the most exciting drugs in the pipeline right now.

Drug is the only respiratory therapy that can be given at home every 8 weeks.

New HIV prevention drug not indicated for women.

Drugstore retailers pull ranitidine and Zantac products off the shelves due to cancer concerns.

Drug is first 8-week treatment approved for this type of HCV.

How the first oral GLP-1 oral treatment for type 2 diabetes is unique and how it will be priced compared to other GLP-1 medications.

FDA limits packaging for this OTC medication.

Fentanyl citrate and ephedrine sulfate are among the medications affected.

FDA is evaluating risks to patients.

Targeted therapy gives new hope to patients with an aggressive form of lung cancer.